{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00025825", "CSN": null, "TRF": "ORD_1548408_01", "MRN": "45003609", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1265250", "clinicalId": "1266613", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1548408_01", "SampleName": "US1478907.01", "Version": "0", "Sample": {"FM_Id": "ORD_1548408_01", "SampleId": "US1478907.01", "BlockId": "S111-65111H", "TRFNumber": "ORD_1548408_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2023_01_18", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "80", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10023", "MRN": "45003609", "FullName": "\u8a31\u6210\u771f ", "FirstName": "Cheng Chen", "LastName": "Hsu", "SubmittedDiagnosis": "neuroendocrine carcinoma", "Gender": "Female", "DOB": "1981_02_10", "OrderingMD": "\u984f\u660e\u8ce2", "OrderingMDId": "109266", "Pathologist": "\u6797\u58eb\u582f", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Colon", "CollDate": "2022_01_11", "ReceivedDate": "2023-02-01 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Neuroendocrine carcinoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "19", "clinicalTrialCount": "0", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "ATR", "isVUS": "true", "variantName": "amplification"}, {"geneName": "BCL6", "isVUS": "true", "variantName": "amplification"}, {"geneName": "FGF12", "isVUS": "true", "variantName": "amplification"}, {"geneName": "KLHL6", "isVUS": "true", "variantName": "amplification"}, {"geneName": "MAP3K13", "isVUS": "true", "variantName": "amplification"}, {"geneName": "MEN1", "isVUS": "true", "variantName": "G508D"}, {"geneName": "NOTCH1", "isVUS": "true", "variantName": "E944G"}, {"geneName": "PIK3CA", "isVUS": "true", "variantName": "amplification"}, {"geneName": "PIK3CB", "isVUS": "true", "variantName": "amplification"}, {"geneName": "PRKCI", "isVUS": "true", "variantName": "amplification"}, {"geneName": "SETD2", "isVUS": "true", "variantName": "R984G"}, {"geneName": "SMARCA4", "isVUS": "true", "variantName": "G1162S"}, {"geneName": "SOX2", "isVUS": "true", "variantName": "amplification"}, {"geneName": "TBX3", "isVUS": "true", "variantName": "L112I"}, {"geneName": "TERC", "isVUS": "true", "variantName": "amplification"}, {"geneName": "TIPARP", "isVUS": "true", "variantName": "amplification"}, {"geneName": "ZNF217", "isVUS": "true", "variantName": "M34I"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_high (MSI_H) has been observed at high frequency in endometrial cancers (14_33%)(Santin et al., ASCO 2016; Abstract 414, Zighelboim et al., 2007; 17513808, Hampel et al., 2006; 16885385, Stelloo et al., 2016; 27006490, Kanopiene et al., 2014; 25458958, Black et al., 2006; 16549821, Nout et al., 2012; 22609107, Steinbakk et al., 2011; 21547578, Bilbao et al., 2010; 20005452), colorectal cancers (CRCs; 10_15%)(Guastadisegni et al., 2010; 20627535, Pawlik et al., 2004; 15528785, Kocarnik et al., 2015; 26337942, Cancer Genome Atlas Network., 2012; 22810696, Lal et al., 2015; 25949894), and gastric cancers (12_35%)(Hiyama et al., 2004; 15209621, Wu et al., 1998; 9537253, dos Santos et al., 1996; 8536886, Fang et al., 2013; 23555086) and at lower frequencies in many other tumor types, including esophageal (Hall et al., 2016; ASCO Gastrointestinal Cancer Symposium Abstract 528, Farris et al., 2011; 21422910), small bowel (Gingras et al., 2015; AACR Pancreatic Cancer Abstract PR06, Agaramet al., 2010; 20395525, Ruemmele et al., 2009; 19252434, Planck et al., 2003; 12627520, Hibi et al., 1995; 7775257, Muneyuki et al., 2000; 11117578), hepatobiliary (Zhang et al., 2005; 15918185, Chiappini et al., 2004; 14656944, Suto et al., 2001; 11223838, Momoi et al., 2001; 11580146, Liengswangwong et al., 2003; 14506736, Moy et al., 2015; 25680569, Yoshida et al., 2000; 11063221), prostate (Cheng et al., 2016; Genitourinary Cancers Symposium Abstract 251, Pritchard et al., 2014; 25255306, Azzouzi et al., 2007; 17233803, Burger et al., 2006; 16924473), and urinary tract carcinomas (Harper et al., 2015; USCAP Abstract 905, Bai et al., 2013; 23690119, Giedl et al., 2014; 25319978, Yamamoto et al., 2006; 16675567). In one study, MSI_H status was associated with a positive prognostic effect in patients with gastric cancer treated with surgery alone and a negative predictive effect in patients treated with chemotherapy (Smyth et al., 2015; ASCO Gastrointestinal Cancers Symposium Abstract 62). Data regarding the role of MSI_H on prognosis and survival in endometrial cancer are conflicting (Zighelboim et al., 2007; 17513808, Kanopiene et al., 2014; 25458958, Bilbao_Sieyro et al., 2014; 25026289, Mackay et al., 2010; 20304627, Steinbakk et al., 2011; 21547578, Arabi et al., 2009; 19275958, Black et al., 2006; 16549821). However, studies specifically analyzing early stage endometrial cancer have reported a correlation between MSI_H and decreased survival (Stelloo et al., 2016; 27006490, Mackay et al., 2010; 20304627, Nout et al., 2012; 22609107, Bilbao et al., 2010; 20005452), thereby suggesting that MSI_H predicts for poor prognosis in this subset of endometrial tumors. On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "05", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "05"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). One study including carcinoids, undifferentiated neuroendocrine carcinomas, and undifferentiated small cell carcinomas of unknown primary reported median tumor mutational burden (TMB) of 1.8, 2.7, and 6.3 Muts/Mb and high TMB (>20 Muts/Mb) in 1.4%, 6.1%, and 8.5% of cases, respectively (FMI_Chalmers et al., 2017; 28420421). In general, studies have reported relatively low median TMB and low frequencies of high TMB in carcinoids and neuroendocrine carcinomas of various tissues of origin (Lawrence et al., 2013; 23770567, FMI_Chalmers et al., 2017; 28420421). Among lung cancers, small cell lung cancer (SCLC) has been reported to have a median TMB of 8_10 Muts/Mb, with 40% of SCLC harboring a TMB of >10 Muts/Mb. One study including lung large cell neuroendocrine carcinomas (LCNEC) reported an average nonsynonymous TMB of 10.5 Muts/Mb and another reported that 46% of LCNEC cases had a TMB >10 Muts/Mb (Rekhtman et al., 2016; 26960398, FMI_Chalmers et al., 2017; 28420421). For small intestine neuroendocrine tumors, one study reported a TMB of \u226510 Muts/Mb in 5.8% (1/17) of cases (Shao et al., 2020; 33119110). In Merkel cell carcinoma, TMB has been reported to be significantly higher in Merkel cell polyomavirus (MCPyV)_negative cases (mean TMB 10_22 Muts/Mb) than in MCPyV_positive cases (mean TMB 0.2_0.4 Muts/Mb) (Harms et al., 2015; 26238782, Goh et al., 2016; 26655088). In small cell carcinoma of the ovary, hypercalcemic type, low TMB (<6 Muts/Mb) was reported in 15/16 (94%) cases with classic morphology and SMARCA4 mutations, whereas high TMB (90 and 360 Muts/Mb) was found in 2/2 cases with pure large cell variant morphology and wildtype SMARCA4 (Lin et al., 2017; 29102090). In 1 retrospective study of patients with advanced neuroendocrine tumors not treated with immunotherapy, tumor mutational burden (TMB)_high (\u226510 Muts/Mb) was not correlated with any significant difference in OS compared with TMB_low (\u2264 10 Muts/Mb) measured in tissue samples (10.4 vs. 6.4 months, adjusted HR = 0.83) (Shao et al., 2020; 33119110). The impact of TMB on the prognosis and clinicopathological features of lung neuroendocrine cancers is unclear; large cell neuroendocrine carcinoma (LCNEC) cases with small cell lung cancer_like molecular features were reported to have significantly higher proliferative activity, as well as a trend toward better clinical benefit from treatment with chemotherapy, than non_small cell lung cancer_like tumors, but the average TMB was not significantly different between the two subsets of LCNEC (Rekhtman et al., 2016; 26960398). MCPyV_negative Merkel cell carcinoma (MCC), associated with higher TMB, has been reported to have a higher number of predicted tumor neoantigens and a significantly higher UV mutation signature than MCPyV_positive MCC (Harms et al., 2015; 26238782, Goh et al., 2016; 26655088). Within MCPyV_negative MCC tumors, the mutational burden has been reported to be significantly higher in PD_L1_positive tumors (more than 1% positive tumor and macrophage cells by immunohistochemistry) than in PD_L1_negative tumors (Wong et al., 2015; 26627015). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": null, "References": {"Reference": [{"number": "0", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "1", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "2", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "3", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "4", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "5", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "6", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "7", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "8", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "9", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "10", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "11", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "12", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "13", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "14", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "15", "ReferenceId": "23770567", "FullCitation": "Lawrence MS, et al. Nature (2013) pmid: 23770567", "Include": "true"}, {"number": "16", "ReferenceId": "26960398", "FullCitation": "Rekhtman N, et al. Clin. Cancer Res. (2016) pmid: 26960398", "Include": "true"}, {"number": "17", "ReferenceId": "33119110", "FullCitation": "Shao C, et al. JAMA Netw Open (2020) pmid: 33119110", "Include": "true"}, {"number": "18", "ReferenceId": "26238782", "FullCitation": "Harms PW, et al. Cancer Res. (2015) pmid: 26238782", "Include": "true"}, {"number": "19", "ReferenceId": "26655088", "FullCitation": "Goh G, et al. Oncotarget (2016) pmid: 26655088", "Include": "true"}, {"number": "20", "ReferenceId": "29102090", "FullCitation": "Lin DI, et al. Gynecol. Oncol. (2017) pmid: 29102090", "Include": "true"}, {"number": "21", "ReferenceId": "26627015", "FullCitation": "Wong SQ, et al. Cancer Res. (2015) pmid: 26627015", "Include": "true"}, {"number": "22", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "23", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "24", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "25", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "26", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "27", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "28", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "29", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "30", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "31", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "32", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "33", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "34", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "35", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "36", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "37", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "38", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "39", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "40", "ReferenceId": "17513808", "FullCitation": "Zighelboim I, et al. J. Clin. Oncol. (2007) pmid: 17513808", "Include": "true"}, {"number": "41", "ReferenceId": "16885385", "FullCitation": "Hampel H, et al. Cancer Res. (2006) pmid: 16885385", "Include": "true"}, {"number": "42", "ReferenceId": "27006490", "FullCitation": "Stelloo E, et al. Clin. Cancer Res. (2016) pmid: 27006490", "Include": "true"}, {"number": "43", "ReferenceId": "25458958", "FullCitation": "Kanopien\u0117 D, et al. Medicina (Kaunas) (2014) pmid: 25458958", "Include": "true"}, {"number": "44", "ReferenceId": "16549821", "FullCitation": "Black D, et al. J. Clin. Oncol. (2006) pmid: 16549821", "Include": "true"}, {"number": "45", "ReferenceId": "22609107", "FullCitation": "Nout RA, et al. Gynecol. Oncol. (2012) pmid: 22609107", "Include": "true"}, {"number": "46", "ReferenceId": "21547578", "FullCitation": "Steinbakk A, et al. Cell Oncol (Dordr) (2011) pmid: 21547578", "Include": "true"}, {"number": "47", "ReferenceId": "20005452", "FullCitation": "Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) pmid: 20005452", "Include": "true"}, {"number": "48", "ReferenceId": "20627535", "FullCitation": "Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535", "Include": "true"}, {"number": "49", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "50", "ReferenceId": "15209621", "FullCitation": "Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) pmid: 15209621", "Include": "true"}, {"number": "51", "ReferenceId": "9537253", "FullCitation": "Wu MS, et al. Cancer Res. (1998) pmid: 9537253", "Include": "true"}, {"number": "52", "ReferenceId": "8536886", "FullCitation": "dos Santos NR, et al. Gastroenterology (1996) pmid: 8536886", "Include": "true"}, {"number": "53", "ReferenceId": "23555086", "FullCitation": "Fang WL, et al. Biomed Res Int (2013) pmid: 23555086", "Include": "true"}, {"number": "54", "ReferenceId": "21422910", "FullCitation": "Farris AB, et al. Am. J. Surg. Pathol. (2011) pmid: 21422910", "Include": "true"}, {"number": "55", "ReferenceId": "20395525", "FullCitation": "Agaram NP, et al. Am. J. Clin. Pathol. (2010) pmid: 20395525", "Include": "true"}, {"number": "56", "ReferenceId": "19252434", "FullCitation": "Ruemmele P, et al. Am. J. Surg. Pathol. (2009) pmid: 19252434", "Include": "true"}, {"number": "57", "ReferenceId": "12627520", "FullCitation": "Planck M, et al. Cancer (2003) pmid: 12627520", "Include": "true"}, {"number": "58", "ReferenceId": "7775257", "FullCitation": "Hibi K, et al. Jpn. J. Cancer Res. (1995) pmid: 7775257", "Include": "true"}, {"number": "59", "ReferenceId": "11117578", "FullCitation": "Muneyuki T, et al. Dig. Dis. Sci. (2000) pmid: 11117578", "Include": "true"}, {"number": "60", "ReferenceId": "15918185", "FullCitation": "Zhang SH, et al. World J. Gastroenterol. (2005) pmid: 15918185", "Include": "true"}, {"number": "61", "ReferenceId": "14656944", "FullCitation": "Chiappini F, et al. Carcinogenesis (2004) pmid: 14656944", "Include": "true"}, {"number": "62", "ReferenceId": "11223838", "FullCitation": "Suto T, et al. J Surg Oncol (2001) pmid: 11223838", "Include": "true"}, {"number": "63", "ReferenceId": "11580146", "FullCitation": "Momoi H, et al. J. Hepatol. (2001) pmid: 11580146", "Include": "true"}, {"number": "64", "ReferenceId": "14506736", "FullCitation": "Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736", "Include": "true"}, {"number": "65", "ReferenceId": "25680569", "FullCitation": "Moy AP, et al. Virchows Arch. (2015) pmid: 25680569", "Include": "true"}, {"number": "66", "ReferenceId": "11063221", "FullCitation": "Yoshida T, et al. J. Gastroenterol. (2000) pmid: 11063221", "Include": "true"}, {"number": "67", "ReferenceId": "25255306", "FullCitation": "Pritchard CC, et al. Nat Commun (2014) pmid: 25255306", "Include": "true"}, {"number": "68", "ReferenceId": "17233803", "FullCitation": "Azzouzi AR, et al. BJU Int. (2007) pmid: 17233803", "Include": "true"}, {"number": "69", "ReferenceId": "16924473", "FullCitation": "Burger M, et al. J. Mol. Med. (2006) pmid: 16924473", "Include": "true"}, {"number": "70", "ReferenceId": "23690119", "FullCitation": "Bai S, et al. Am. J. Clin. Pathol. (2013) pmid: 23690119", "Include": "true"}, {"number": "71", "ReferenceId": "25319978", "FullCitation": "Giedl J, et al. Am. J. Clin. Pathol. (2014) pmid: 25319978", "Include": "true"}, {"number": "72", "ReferenceId": "16675567", "FullCitation": "Yamamoto Y, et al. Clin. Cancer Res. (2006) pmid: 16675567", "Include": "true"}, {"number": "73", "ReferenceId": "25026289", "FullCitation": "Bilbao_Sieyro C, et al. Oncotarget (2014) pmid: 25026289", "Include": "true"}, {"number": "74", "ReferenceId": "20304627", "FullCitation": "Mackay HJ, et al. Eur. J. Cancer (2010) pmid: 20304627", "Include": "true"}, {"number": "75", "ReferenceId": "19275958", "FullCitation": "Arabi H, et al. Gynecol. Oncol. (2009) pmid: 19275958", "Include": "true"}, {"number": "76", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "77", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "78", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_01_29 23:22:03", "OpName": "Tyler Janovitz, MD, PhD | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Tyler Janovitz, MD, PhD | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "908x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "5 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": {"comment": {"commentedBy": "Tyler Janovitz, MD, PhD", "commentedDts": "2023_01_29T23:20:17.000Z", "text": "This assay is not validated to delineate single copy losses or low_level copy gains or to identify viral DNA. Manual review of the sequencing data revealed focal and segmental copy number alterations. These findings are consistent with adequate tumor purity for detection of targetable alterations. Manual review of the sequencing data also suggests the presence of HPV_18. Ancillary molecular testing for high_risk HPV could be considered to confirm this finding if clinically indicated."}}, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease_ontology": "Unknown primary undifferentiated neuroendocrine carcinoma", "flowcell_analysis": "2000027151", "gender": "female", "pathology_diagnosis": "Small cell carcinoma", "percent_tumor_nuclei": "80", "pipeline_version": "v3.19.0", "purity_assessment": "38.4", "specimen": "ORD_1548408_01*US1478907.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1548408_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Colon", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "947.34", "name": "SQ_US1478907.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.461", "cds_effect": "3484G>A", "depth": "410", "equivocal": "false", "functional_effect": "missense", "gene": "SMARCA4", "percent_reads": "46.1", "position": "chr19:11141507", "protein_effect": "G1162S", "status": "unknown", "strand": "+", "transcript": "NM_003072", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}, {"allele_fraction": "0.0909", "cds_effect": "2831_2832AG>GT", "depth": "726", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH1", "percent_reads": "9.09", "position": "chr9:139404322", "protein_effect": "E944G", "status": "unknown", "strand": "_", "transcript": "NM_017617", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}, {"allele_fraction": "0.4897", "cds_effect": "1523G>A", "depth": "678", "equivocal": "false", "functional_effect": "missense", "gene": "MEN1", "percent_reads": "48.97", "position": "chr11:64572131", "protein_effect": "G508D", "status": "unknown", "strand": "_", "transcript": "NM_130801", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}, {"allele_fraction": "0.4874", "cds_effect": "102G>A", "depth": "835", "equivocal": "false", "functional_effect": "missense", "gene": "ZNF217", "percent_reads": "48.74", "position": "chr20:52199264", "protein_effect": "M34I", "status": "unknown", "strand": "_", "transcript": "NM_006526", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}, {"allele_fraction": "0.4778", "cds_effect": "334C>A", "depth": "630", "equivocal": "false", "functional_effect": "missense", "gene": "TBX3", "percent_reads": "47.78", "position": "chr12:115120672", "protein_effect": "L112I", "status": "unknown", "strand": "_", "transcript": "NM_016569", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}, {"allele_fraction": "0.4513", "cds_effect": "2950A>G", "depth": "995", "equivocal": "false", "functional_effect": "missense", "gene": "SETD2", "percent_reads": "45.13", "position": "chr3:47163176", "protein_effect": "R984G", "status": "unknown", "strand": "_", "transcript": "NM_014159", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "7", "equivocal": "true", "gene": "ATR", "number_of_exons": "47 of 47", "position": "chr3:142164726_142305768", "ratio": "1.93", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}, {"copy_number": "7", "equivocal": "true", "gene": "PIK3CB", "number_of_exons": "23 of 23", "position": "chr3:138374230_138478185", "ratio": "1.97", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}, {"copy_number": "7", "equivocal": "true", "gene": "TERC", "number_of_exons": "3 of 3", "position": "chr3:169482000_169483150", "ratio": "2.1", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}, {"copy_number": "7", "equivocal": "true", "gene": "TIPARP", "number_of_exons": "5 of 5", "position": "chr3:156395486_156422920", "ratio": "2.0", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}, {"copy_number": "7", "equivocal": "true", "gene": "BCL6", "number_of_exons": "8 of 8", "position": "chr3:187439170_187451481", "ratio": "1.92", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}, {"copy_number": "7", "equivocal": "true", "gene": "KLHL6", "number_of_exons": "7 of 7", "position": "chr3:183209714_183273441", "ratio": "2.03", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}, {"copy_number": "7", "equivocal": "true", "gene": "FGF12", "number_of_exons": "6 of 6", "position": "chr3:191820777_192487207", "ratio": "2.04", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}, {"copy_number": "7", "equivocal": "true", "gene": "SOX2", "number_of_exons": "5 of 5", "position": "chr3:181383236_181476165", "ratio": "2.23", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}, {"copy_number": "7", "equivocal": "true", "gene": "PRKCI", "number_of_exons": "18 of 18", "position": "chr3:169940443_170020936", "ratio": "1.95", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}, {"copy_number": "7", "equivocal": "true", "gene": "PIK3CA", "number_of_exons": "20 of 20", "position": "chr3:178875270_178996445", "ratio": "1.99", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}, {"copy_number": "7", "equivocal": "true", "gene": "MAP3K13", "number_of_exons": "15 of 15", "position": "chr3:185003347_185200258", "ratio": "1.97", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "4.83", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": {"organism": "HPV_18", "reads_per_million": "89", "status": "unknown", "dna_evidence": {"sample": "SQ_US1478907.01_1"}}}}}}}